The EPS beat and strong cash runway are positive, but the widening net loss and pre-revenue clinical-stage status limit near-term catalysts. Monitor BASECAMP enrollment completion in Q3 2026 and any TRAILHEAD data updates throughout 2026 as key inflection points.
Price Chart
Executive Summary
Satellos reported Q1 2026 EPS of -$0.53, a GAAP miss vs consensus of -$0.59 (beat by 10.2%), but the Street-convention EPS of -$0.47 for Q4 2025 suggests the -$0.53 is in line with expectations. The company highlighted strong cash position of $69.9M (up from $27.7M) providing runway through 2027, and clinical progress with BASECAMP enrollment on track to complete in Q3 2026. The net loss widened to $9.8M from $6.1M YoY due to increased R&D spending on clinical trials.
Key Financial Metrics
Key Facts
- EPS of -$0.53 vs consensus -$0.59 (beat by 10.2%)
- Cash and equivalents of $69.9M, up from $27.7M at year-end 2025, providing runway through 2027
- Net loss of $9.8M vs $6.1M in Q1 2025, driven by higher R&D expenses
- BASECAMP Phase 2 pediatric study enrollment on track to complete in Q3 2026 with 11 active sites
- TRAILHEAD Phase 2 adult study initiated in the U.S. with up to 30 participants planned
- Company raised $57M in February 2026 equity offering and uplisted to Nasdaq
Financial Impact
EPS beat of 10.2% vs consensus, but net loss widened 61% YoY to $9.8M; cash position strengthened to $69.9M
Risk Factors
- Clinical trial enrollment or data delays could pressure the stock
- Cash burn rate of ~$9.8M/quarter implies ~7 quarters of runway, but further dilution may be needed before revenue
- Pre-revenue biotech with no approved products; stock is highly sensitive to pipeline news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | awaiting T+20 | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | awaiting T+20 | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | awaiting T+20 | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | awaiting T+20 | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | awaiting T+20 | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers